The Prototype: There's Plenty Of Water On Mars For Future Colonists
A Martian glacier seen from the Mars Reconnaissance Orbiter NASA
A lthough there are many who dream about one day living on Mars, there's been one challenge to plans for eventually settling on the Red Planet: access to water, which would be vital for any kind of community. But new findings show that water might be easier to find than expected. It turns out that Martian glaciers, once thought to be mostly rock intermixed with ice, are actually over 80% ice in regions across the planet's surface.
In trying to figure out the puzzle of Martian glaciers, the researchers behind the new study realized that previous efforts to determine their composition were inconsistent. So one of the first things they did was standardize their approach. Using a radar instrument on NASA's Mars Reconnaissance Orbiter, which has been circling the planet for nearly two decades, the scientists found that the glaciers were mostly ice that was covered in rocks and dust. Moreover, they found that glaciers on different parts of Mars–even on opposite hemispheres–had virtually identical ratios of water.
That will make it easier for future Martian citizens to access water, increasing the odds that a permanent colony on the planet might happen one day.
Stay tuned. How AI And Mini-Organs Could Replace Testing Drugs On Animals
Illustration by Macy Sinreich for Forbes; Images by Svetlana Shamshurina; Serhii Borodin; Kristina Velickovic; Nosyrevy via Getty Images
At Children's Mercy Hospital in Kansas City, researchers have created something extraordinary: tiny, beating lab-grown 'hearts.' Visible only under a microscope, the diminutive innards are called organoids. They can be grown in a matter of days from a patient's own stem cells, and their doctors use them to screen for the best medicine for their condition, sparing months of trial and error.
They're also core to the future of drug testing, and someday perhaps the end of the lab rat.
Animal testing has been mandated by law since 1937, when a new formulation of a common antibiotic had a poisonous new ingredient — and killed more than 100 people. Nearly a century later, drugs are still being pulled from shelves because they have toxic effects, even though animal testing showed they were safe. Now, politicians, scientists and entrepreneurs are pushing for new, more accurate ways to test drugs before they get to human clinical trials — potentially saving lives and billions of dollars in the process.
In 2022, a group of scientists ran an experiment with 27 known drug compounds that animal studies had shown to be safe. Some of them had turned out to have toxic side effects and had been pulled from the market after they'd killed people. The researchers tested the 27 compounds on a new technology called 'organ-on-a-chip': similar to organoids, 'organ chips' have clusters of cells embedded in a diminutive electronic device that can simulate an organ's behavior. The researchers found that liver organs-on-a-chip accurately predicted which compounds were dangerous, an advancement that might someday lead to significant cost savings in the extremely expensive drug development process. More accurate testing using organ chips could save the industry over $3 billion a year, the study's authors calculated.
On top of safety, cost is another reason to move away from animal testing. Today, pharma companies often spend more than $2 billion to bring a single drug to market, with the industry spending nearly $300 billion a year on research & development. But despite these vast R&D expenditures, more than 90% of drug candidates fail. It's a wasteful process, contributing to the flabbergasting prices of drugs that do make it to market.
Read the whole story at Forbes . DISCOVERY OF THE WEEK: MRNA VACCINES MIGHT PREVENT HIV INFECTION
Scientists have made great strides in treating HIV since the 1980s, though after decades of work, a vaccine still remains elusive. But a new study of an mRNA vaccine against the virus offers hope. A clinical trial of 108 healthy adults found that it triggered the immune system to develop antibodies against HIV while having few serious side effects. More study is needed before any kind of vaccine hits the market, but the authors stated that this approach using mRNA vaccines offers a lot of future promise. FINAL FRONTIER: THIS STAR SYSTEM MIGHT HAVE FIVE LIVABLE PLANETS
Astronomers have found a new planet around L 98-59, a red dwarf star that's just 35 light-years away from Earth. What's interesting about the planet is that it lies in the 'habitable zone' of the star–meaning it's at the right distance for temperatures allowing liquid water to flow. Even more interesting: this is the fifth such planet to be found around L 98-59 over the past decade. All of the planets have roughly similar masses and sizes to Earth, as well. Next up, astronomers hope to study the system using the recently launched James Webb Space Telescope to learn more about these worlds. WHAT ELSE I WROTE THIS WEEK
In my other newsletter, InnovationRx, Amy Feldman and I looked at how Trump's tariffs on European drugs will hit American consumers, Halle Berry's menopause startup, how robots eliminate the need to do open heart surgery for a valve replacement, and more.
I filled in this week on my colleague Thomas Brewster's cybersecurity newsletter, The Wiretap, where I took a look at how OpenAI's agent casually proved it wasn't a bot, pro-Ukrainian hackers taking down Russia's national airline and Apple's efforts to combat text message spam. SCIENCE AND TECH TIDBITS
Self-driving taxi company Waymo announced that it will be expanding its services to Dallas next year. The robot cars are currently available in five U.S. cities and will also be launching in Miami and Washington D.C. in 2026.
Elon Musk's brain-computer interface company Neuralink is joining a research project aimed at developing a bionic eye, reports Bloomberg .
Fusion power company Helion has broken ground on its first nuclear fusion plant in Malaga, Washington. The company has a contract with Microsoft to power its data centers in the region.
Commercial space company Firefly Aerospace, which is so far the only company to successfully land a spacecraft on the Moon's surface, has been awarded a $177 million contract from NASA to deliver rovers and scientific instruments to the lunar South Pole. PRO SCIENCE TIP: GET IN THE TRENCHES IF YOU WANT TO SPEAK YOUR MIND AT WORK
Two new studies on the workplace both shared a result you may not find surprising: the folks who tend to agree with their bosses a lot tend to get promoted more than people who challenge them. That's true even though there's a wealth of papers finding that empowering employees willing to challenge the company line is better for results in the long run. But there's one way the studies found that internal critics can still get promoted and empowered: if they exhibit helpful behaviors and are willing to roll up their sleeves when the going gets tough.
'If an employee was willing to buckle down and put in the work when the chips were down, such as helping leaders with heavy workloads, leaders were not threatened when that employee highlighted problems or raised concerns,' study co-author Bradley Kirkman said in a statement. WHAT'S ENTERTAINING ME THIS WEEK
I recently read the book Assassin's Anonymous by Rob Hart. It's a spin on the old story of the world's deadliest assassin, who has been retired until his past inevitably catches up to him. But there's a catch: he's also in a 12-step program with other assassins, working to break the patterns that led him to become a killer, and he's about to get his one-year chip. So now he needs to deal with his enemies using non-fatal solutions. It's a perfect summer beach read. MORE FROM FORBES Forbes Thwarted By Regulators, Vindicated By Wall Street: Design Startup Figma's CEO Is Now A Multi-Billionaire By Iain Martin Forbes How A 60-Year-Old Drug Developer Built A $4.4 Billion Biotech Treating 'Butterfly Skin Disease' By Amy Feldman Forbes How Halle Berry Became The New Face Of Menopause By Maggie McGrath
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
27 minutes ago
- Gizmodo
Dental Floss Could Deliver Next-Gen Vaccines, No Needles Required
Flu shot season is around the corner, and while injections remain the most common form of vaccination, scientists are working hard to find other ways to deliver inoculations that don't involve shoving a needle into your flesh. And in a new study, researchers think they might have found another novel approach: dental floss. In the new work, a team of scientists based in the U.S. demonstrated how this might work on lab mice, finding that vaccine delivery via dental floss was more effective at stimulating antibody production than if the vaccine was delivered under the mice's tongues and about as effective as a nasal spray delivery method. If the results hold true for humans, then some vaccines could be given via tooth tape and without the need for needles. 'Here we show that flat tape dental floss can deliver vaccines through the junctional epithelium of the gingival sulcus, exploiting its naturally leaky properties,' the researchers wrote in the study, which was published in July in the journal Nature Biomedical Engineering. The junctional epithelium is the technical term for the deep tissue between the tooth and the gum. Epithelial tissues are one of three layers of so-called mucosal surfaces, which are the membranes that lubricate and protect your body's organs and cavities, including your nose, mouth, and intestines. Many pathogens like influenza and Covid-19 can enter the body through these mucosal surfaces. 'If a vaccine is given by injection, antibodies are primarily produced in the bloodstream throughout the body, and relatively few antibodies are produced on mucosal surfaces,' Harvinder Singh Gill, co-author of the study and a professor in Nanomedicine at North Carolina State University, explained in a statement. 'But we know that when a vaccine is given via the mucosal surface, antibodies are stimulated not only in the bloodstream, but also on mucosal surfaces.' 'This improves the body's ability to prevent infection, because there is an additional line of antibody defense before a pathogen enters the body,' he added. Because the tissue in between our teeth and gums is more permeable than other similar tissues, like those lining your stomach, lungs, and intestines, then it should be able to introduce a vaccine into the body relatively easily, triggering the production of antibodies throughout the mucosal layers. To test this idea, the researchers applied peptide flu vaccine on unwaxed dental floss, and then used it to floss the teeth of lab mice. Gill and colleagues then compared the animals' antibody production to that of mice that either received the peptide flu vaccine via a nasal spray or under their tongues. The dental floss vaccine delivered significantly superior antibody production on mucosal surfaces than the under-the-tongue inoculation, and was comparable to the nasal spray. 'This is extremely promising, because most vaccine formulations cannot be given via the nasal epithelium—the barrier features in that mucosal surface prevent efficient uptake of the vaccine,' said Gill, adding that nasal delivery also carries the risk of the vaccine reaching the brain, which could pose safety concerns. 'Vaccination via the junctional epithelium offers no such risk,' he said. The team also tested the floss approach with three other vaccine classes—proteins, inactivated viruses, and mRNA—and revealed that the novel method triggered antibodies both in the bloodstream and mucosal surfaces in all of them. What's more, their efficacy wasn't impeded if the mice consumed food or water right after flossing. To investigate the practicality of the flossing approach, the researchers also tested its mechanics with humans. Using floss picks, they coated the tape with food dye and asked study participants to try and get it as deep between their teeth and their gums as they could. Participants were able to deposit around 60% of the dye in the gum pocket, indicating that vaccine-coated floss picks could be an effective way to deliver vaccines to that tissue. As for costs, the researchers think that it would be similar in price to other vaccine delivery techniques. However, there are some inherent limitations to a floss vaccine. 'For example, it can only be used for individuals with teeth,' the researchers explained in the study. 'Therefore, this approach cannot be used in neonates [newborns] until they experience teeth eruption, which typically occurs at around 6 months of age. Further, the impact of gingival tissue infection on vaccination is unclear. Additional studies are required to answer this question.'
Yahoo
3 hours ago
- Yahoo
Artemis II on track for moon flight, looking to launch as early as February 2026
The crew of 4 astronauts undertaking NASA's 2026 Artemis II mission say the moon flight is on track for its launch next year. Speaking at Kennedy Space Center in Cape Canaveral, Florida on July 30, the crew say there are possible openings for a launch in February.
Gizmodo
3 hours ago
- Gizmodo
A Mystery Killer Wiped Out Billions of Sea Stars. Biologists Just Solved the Case.
Columbo, eat your heart out: A team of scientists has just solved a massive marine murder mystery, nabbing the culprit behind the deaths of billions of sea stars over the past decade. In a new study, researchers in the U.S. and Canada argue that the bacterial cousin of cholera is behind the epidemic. Through a series of experiments involving both wild and captive sea stars, they found evidence that Vibrio pectenicida is the likely cause of sea star wasting disease—a devastating condition that causes the invertebrates to decay and essentially 'melt.' The team's findings appear to be well supported with evidence, Zak Swartz, a biologist specializing in sea stars at the Marine Biological Laboratory who was not involved with the study, told Gizmodo. 'This study definitely passes the sniff test for me. It seems quite convincing that V. pectenicida bacteria are at least one causative agent of SSWS,' Swartz said. Sea stars started disappearing in 2013, when a massive outbreak of SSWD struck the North American Pacific coast. The disease swept the seas from Alaska to Mexico, decimating more than 20 different species of sea stars, which are also known as starfish. Afflicted creatures first develop visible lesions on their skin, and then their tissue starts to decay. Death by SSWD is often swift, killing the sea star within days. There have been other mass sea star die-offs in recent decades, but the sheer scale and spread of this outbreak makes it possibly the largest marine disease epidemic ever recorded in the wild. Researchers estimate that one particular sea star species, Pycnopodia helianthoides, has lost 90% of its population to SSWD. The destruction has also dramatically changed the environments where the sea stars once thrived. In the aftermath of SSWD outbreaks, some areas have also lost kelp forests, as sea urchins—once kept in check by sea stars—decimated the underwater forests. Marine scientists have been looking for the cause of SSWD ever since its emergence. And like any great mystery, there have been some twists. In 2014, a research team published a paper that argued a sea star-associated densovirus caused SSWD. But subsequent studies showed that this virus—or any potentially pathogenic virus for that matter—could only be found in a minority of affected species, ruling it out as the likeliest suspect. Swartz noted that some Vibrio bacteria, however, were already known to cause disease in echinoderms—the broad group of marine invertebrates that includes sea stars. 'So in a sense, it feels like the answer was hiding right under our noses. It makes total sense,' he said. Several species of Vibrio can also sicken humans, including cholera (Vibrio cholerae). The researchers didn't set out on this study with V. pectenicida in mind from the get-go. They exhaustively studied samples of sea stars with SSWD and healthy specimens, eventually finding that only the diseased sea stars carried high levels of the bacteria in their coelomic fluid (the invertebrate version of blood). The researchers were then able to isolate and grow new populations of the bacteria collected from the sick sea stars. And when they exposed healthy sea stars to these bacteria, the creatures rapidly developed and died from SSWD. These experiments are the same sort used to identify and conclusively show a particular germ causes a specific disease in humans, strengthening the team's case. Further analysis also revealed that SSWD is caused by a specific strain of the bacteria, called FHCF-3. 'Here we use controlled exposure experiments, genetic datasets, and field observations to demonstrate that the bacterium, Vibrio pectenicida strain FHCF-3, is a causative agent of SSWD,' the authors wrote in their paper, published Monday in Nature Ecology and Evolution. Though the mystery of what causes SSWD appears solved, Swartz and the study authors note that there are still several important unanswered questions. For example, scientists aren't sure exactly how the outbreaks start. It's possible the bacteria could spread via sea stars' shared food, or through physical contact with other sea stars. Low levels of the bacteria may also always be circulating in the environment, but only become a major problem under specific conditions, like at a certain temperature (Vibrio bacteria in general thrive in warmer water). Still, given that SSWD remains a threat to sea stars, simply knowing its cause could boost sea star recovery efforts, the researchers said. It might be possible to find genetic mutations that help sea stars fend off these infections, for instance, enabling scientists to breed sea stars carrying these mutations in captivity with the aim of reintroducing them into the wild to bolster the population's resilience.
